I Read The News Today Oh Boy! 29-Mar-2019

Friday, Mar 29 2019 by

Morning all!

Bioventix ( Bioventix (LON:BVXP) ) – 3600p – £185m – PER 29.3

Interim Results For The 6 Months To End December 2018 – Revenue and PBT up 24%, Cash at £5.5m (£5.6m last time), Interim Dividend up 20%.

I keep missing out here always thinking it looks too expensive. I guess I will just sit and watch it go higher as I always consider it too expensive!

Numis ( Numis (LON:NUM) ) – 255p – £271m – PER 11.1

Trading Update For The 6 Months To End March 2019 – Revenue expected to be -26% lower than last year – Challenging but pipeline stronger in recent weeks.

Too "lumpy" for me to get involved here again at present, possibly ever!

As always, all comment most welcome!

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way


As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. The author may own shares in any companies discussed, all opinions are his/her own & are general/impersonal. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.

Do you like this Post?
14 thumbs up
0 thumbs down
Share this post with friends

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors. more »

LSE Price
Mkt Cap (£m)
P/E (fwd)
Yield (fwd)

Numis Corporation PLC is a United Kingdom-based independent institutional stockbrokers and corporate advisors. The Company offers a range of research, execution, corporate broking and advisory services to companies quoted in the United Kingdom and its investors. The Company's services include research, sales and trading, investment companies, corporate finance, corporate broking, principle capital fund managers limited (PCFM), Numis indices and asset management. The investment company's research-driven approach focuses on specialist or differentiated mandates, including quoted equity, private equity, infrastructure, property, debt and other alternative assets. The corporate finance services include advice and transaction execution in relation to mergers and acquisitions, secondary equity issuance, convertible securities and bonds. The Company serves corporate clients and institutional clients. It is managed as an integrated corporate advisory and stockbroking business. more »

LSE Price
Mkt Cap (£m)
P/E (fwd)
Yield (fwd)

  Is LON:BVXP fundamentally strong or weak? Find out More »

6 Posts on this Thread show/hide all

andrea34l 29th Mar 1 of 6

I have a similar mentality to you, Matylda, with Bioventix (LON:BVXP) and it is not helped by the fact that the turnover is very small, even if margins are high and ROCE is astronomical. A PEG of 3 is not attractive, either. The statement "there is increasing evidence of a plateau in the downstream global vitamin D assay market" sounds like a mild warnings for some point in the future, I'm not sure how much of the turnover relates to vitamin D but I'm assuming it's fairly significant as it features much in the commentary.

Have a nice weekend, thanks for all of this weeks posts.

| Link | Share | 1 reply
MrContrarian 29th Mar 2 of 6

My morning smallcap tweet: Fertile time for Concepta

Concepta (LON:CPT), Mobile Streams (LON:MOS), Renewi (LON:RWI), Parity (LON:PTY), Numis (LON:NUM), Hydrodec (LON:HYR)

Concepta (CPT) Boots to sell myLotus women's fertility and hormone testing kit.
Mobile Streams (MOS) H1 rev halved. Warns on H2. Blames developments amongst the telecom operators and increased regulations in INdia.
Renewi (RWI) Guides 2019 in line but 2020 EBIT around €25m lower (worst case) if no shipments of thermally treated soil from ATM. Dutch authorities require additional tests and may not allow the interim waiver to continue.
Parity Group (PTY) a framework contract for the placement of staff it has with the Scottish government is not being renewed. Guides rev hit of 10% but profit still in line since it is low margin work and better performance is rest of group.
Numis Corporation (NUM) recent trading improved but mkt challenging as stated in Feb so still guides H1 rev down 26%.
HydroDec (HYR) confident volumes & production will exceed its original expectations. US review of the Government's oil recycling strategy seen as hugely positive.

| Link | Share
stepone 29th Mar 3 of 6

In reply to post #463703

Vitamin D for year ending June 2018 was £3.4m from total sales of £7.9m, so, yes, definitely significant.

| Link | Share | 1 reply
andrea34l 29th Mar 4 of 6

In reply to post #463743

Thanks for filling in the gaps, stepone :-) I definitely can't invest on this basis at the moment at this rating.

| Link | Share | 1 reply
matylda 29th Mar 5 of 6

In reply to post #463763

I have the following forecasts, based on a FInnCap 29-Mar-19 note...


Sorry it's so big, no expert in inserting images!

Anyway, on a PER of 30+ I just don't get it and probably never will - I guess my way of valuation simply doesn't work or apply here.

Will include this in my Monthly Parity PEG Price Report for April which I will post here in the next few days all being well.


Blog: Briefed Up
| Link | Share
stepone 29th Mar 6 of 6

One thing to notice is that up to now Bioventix have always beaten the forecasts. So, for year ending June 2018, the forecasts started at £6m revenue, then were increased to 6.3m and then 6.9m, and actual turnover came in at £7.9m (plus 700k backdated royalties). Turnover growth this latest half year was 24% and that's without any significant contribution from Troponin sales, which they expect to increase quickly.

The dividend forecasts exclude the specials - which are significant. Actual dividend for 2019 will be above last years 116p, and way above the 73p forecast.

The royalty model should keep revenues sticky in the long term and the high margins should keep the dividend payouts at a decent level. It's definitely not the bargain it was five years ago, but I am going to keep holding for a while yet.

| Link | Share

Please subscribe to submit a comment

 Are LON:BVXP's fundamentals sound as an investment? Find out More »

Stock Picking Tutorial Centre

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis